Literature DB >> 23476421

Dichloro-phosphinic bis-(2-chloro-eth-yl)amide.

Erqun Song1, Yang Song.   

Abstract

In the title compound, C4H8Cl4NOP, the two chloro-ethyl groups are not related by crystallographic symmetry. The difference in the conformation of the two groups is shown by their N-C-C-Cl torsion angles of 64.57 (15) and 175.62 (10)°.

Entities:  

Year:  2012        PMID: 23476421      PMCID: PMC3588365          DOI: 10.1107/S1600536812049586

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

The title compound is a precursor used in the synthesis of the anti­tumor drug cyclo­phosphamide and its analogues. For information on organo­phospho­rus heterocyclic compounds, see: Surendra Babu et al. (2009 ▶); Srinivasulu et al. (2008 ▶); Krishna et al. (2006 ▶). For the crystal structures of cyclo­phosphamide analogues, see: Camerman & Camerman (1973 ▶); Jones et al. (1996 ▶); Himes et al. (1982 ▶); Camerman et al. (1983 ▶); Perales & García-Blanco (1977a ▶,b ▶); Gałdecki & Głowka (1981 ▶); Boyd et al. (1980 ▶); Shih et al. (1986 ▶). For the pharma­cological activity of cyclo­phosphamide analogues, see: Lin et al. (1980 ▶); Borch & Canute (1991 ▶).

Experimental

Crystal data

C4H8Cl4NOP M = 258.88 Monoclinic, a = 9.0723 (15) Å b = 8.4810 (14) Å c = 13.135 (2) Å β = 101.221 (2)° V = 991.4 (3) Å3 Z = 4 Mo Kα radiation μ = 1.30 mm−1 T = 298 K 0.16 × 0.12 × 0.10 mm

Data collection

Bruker APEXII CCD diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2009 ▶) T min = 0.819, T max = 0.881 9480 measured reflections 3255 independent reflections 2725 reflections with I > 2σ(I) R int = 0.020

Refinement

R[F 2 > 2σ(F 2)] = 0.029 wR(F 2) = 0.090 S = 1.05 3255 reflections 101 parameters H-atom parameters constrained Δρmax = 0.57 e Å−3 Δρmin = −0.46 e Å−3 Data collection: APEX2 (Bruker, 2009 ▶); cell refinement: SAINT (Bruker, 2009 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: SHELXTL (Sheldrick, 2008 ▶); software used to prepare material for publication: SHELXTL and local procedures. Click here for additional data file. Crystal structure: contains datablock(s) I, global. DOI: 10.1107/S1600536812049586/fy2076sup1.cif Click here for additional data file. Supplementary material file. DOI: 10.1107/S1600536812049586/fy2076Isup2.cdx Click here for additional data file. Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536812049586/fy2076Isup3.hkl Click here for additional data file. Supplementary material file. DOI: 10.1107/S1600536812049586/fy2076Isup4.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C4H8Cl4NOPF(000) = 520
Mr = 258.88Dx = 1.735 Mg m3
Monoclinic, P21/cMo Kα radiation, λ = 0.71073 Å
a = 9.0723 (15) ÅCell parameters from 4728 reflections
b = 8.4810 (14) Åθ = 2.3–31.1°
c = 13.135 (2) ŵ = 1.30 mm1
β = 101.221 (2)°T = 298 K
V = 991.4 (3) Å3Block, colourless
Z = 40.16 × 0.12 × 0.10 mm
Bruker APEXII CCD diffractometer3255 independent reflections
Radiation source: fine-focus sealed tube2725 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.020
φ and ω scansθmax = 32.2°, θmin = 2.3°
Absorption correction: multi-scan (SADABS; Bruker, 2009)h = −13→13
Tmin = 0.819, Tmax = 0.881k = −12→12
9480 measured reflectionsl = −19→13
Refinement on F2Secondary atom site location: difference Fourier map
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.029H-atom parameters constrained
wR(F2) = 0.090w = 1/[σ2(Fo2) + (0.0482P)2 + 0.1876P] where P = (Fo2 + 2Fc2)/3
S = 1.05(Δ/σ)max = 0.002
3255 reflectionsΔρmax = 0.57 e Å3
101 parametersΔρmin = −0.46 e Å3
0 restraintsExtinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
Primary atom site location: structure-invariant direct methodsExtinction coefficient: 0.0064 (13)
Geometry. All e.s.d.'s (except the e.s.d. in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell e.s.d.'s are taken into account individually in the estimation of e.s.d.'s in distances, angles and torsion angles; correlations between e.s.d.'s in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell e.s.d.'s is used for estimating e.s.d.'s involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > σ(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C10.38633 (16)0.82538 (16)0.87493 (12)0.0381 (3)
H1A0.43010.78450.81860.046*
H1B0.46820.85440.93100.046*
C20.2970 (2)0.97152 (18)0.83776 (13)0.0467 (3)
H2A0.21250.94320.78340.056*
H2B0.35991.04470.80870.056*
C30.19521 (15)0.60676 (16)0.83359 (10)0.0353 (3)
H3A0.14290.67690.78020.042*
H3B0.12080.55560.86620.042*
C40.27918 (18)0.48303 (19)0.78420 (13)0.0448 (3)
H4A0.33740.41690.83760.054*
H4B0.34790.53370.74630.054*
Cl10.31341 (5)0.44237 (4)1.05878 (3)0.05244 (12)
Cl30.22968 (5)1.06456 (5)0.94101 (4)0.05789 (13)
Cl20.08981 (4)0.71564 (5)1.05773 (3)0.05103 (12)
Cl40.14781 (6)0.36563 (5)0.69800 (4)0.06145 (14)
N10.29789 (12)0.69934 (13)0.91169 (9)0.0328 (2)
O10.41231 (13)0.76345 (14)1.10623 (8)0.0474 (3)
P10.29887 (4)0.67627 (4)1.03420 (3)0.03356 (10)
U11U22U33U12U13U23
C10.0403 (6)0.0353 (6)0.0409 (7)−0.0035 (5)0.0131 (5)−0.0024 (5)
C20.0600 (9)0.0347 (6)0.0451 (8)−0.0025 (6)0.0094 (7)0.0020 (6)
C30.0376 (6)0.0343 (6)0.0330 (6)0.0004 (5)0.0042 (5)−0.0035 (5)
C40.0481 (8)0.0409 (7)0.0444 (8)−0.0001 (6)0.0067 (6)−0.0131 (6)
Cl10.0676 (3)0.03754 (19)0.0523 (2)0.00726 (15)0.01214 (19)0.01047 (15)
Cl30.0608 (3)0.0414 (2)0.0733 (3)0.00801 (16)0.0174 (2)−0.01022 (18)
Cl20.04327 (19)0.0641 (3)0.0497 (2)0.00731 (16)0.01884 (16)−0.00236 (17)
Cl40.0777 (3)0.0514 (2)0.0521 (3)−0.0121 (2)0.0049 (2)−0.01980 (19)
N10.0376 (5)0.0315 (5)0.0292 (5)−0.0022 (4)0.0062 (4)−0.0026 (4)
O10.0479 (6)0.0540 (6)0.0369 (5)−0.0032 (5)−0.0006 (4)−0.0072 (5)
P10.03567 (17)0.03484 (17)0.02971 (16)0.00247 (12)0.00520 (12)−0.00150 (12)
C1—N11.4732 (18)C3—H3A0.9700
C1—C21.509 (2)C3—H3B0.9700
C1—H1A0.9700C4—Cl41.7800 (16)
C1—H1B0.9700C4—H4A0.9700
C2—Cl31.7767 (17)C4—H4B0.9700
C2—H2A0.9700Cl1—P12.0100 (6)
C2—H2B0.9700Cl2—P12.0081 (6)
C3—N11.4713 (16)N1—P11.6195 (12)
C3—C41.515 (2)O1—P11.4567 (11)
N1—C1—C2114.16 (12)H3A—C3—H3B108.0
N1—C1—H1A108.7C3—C4—Cl4109.25 (11)
C2—C1—H1A108.7C3—C4—H4A109.8
N1—C1—H1B108.7Cl4—C4—H4A109.8
C2—C1—H1B108.7C3—C4—H4B109.8
H1A—C1—H1B107.6Cl4—C4—H4B109.8
C1—C2—Cl3111.13 (11)H4A—C4—H4B108.3
C1—C2—H2A109.4C3—N1—C1118.04 (11)
Cl3—C2—H2A109.4C3—N1—P1120.57 (9)
C1—C2—H2B109.4C1—N1—P1121.02 (9)
Cl3—C2—H2B109.4O1—P1—N1116.78 (7)
H2A—C2—H2B108.0O1—P1—Cl2112.63 (5)
N1—C3—C4111.43 (11)N1—P1—Cl2108.07 (5)
N1—C3—H3A109.3O1—P1—Cl1112.37 (5)
C4—C3—H3A109.3N1—P1—Cl1105.45 (4)
N1—C3—H3B109.3Cl2—P1—Cl1100.01 (2)
C4—C3—H3B109.3
N1—C1—C2—Cl364.57 (15)C3—N1—P1—O1175.23 (10)
N1—C3—C4—Cl4175.62 (10)C1—N1—P1—O1−11.87 (13)
C4—C3—N1—C178.71 (15)C3—N1—P1—Cl2−56.60 (10)
C4—C3—N1—P1−108.18 (13)C1—N1—P1—Cl2116.30 (10)
C2—C1—N1—C375.10 (16)C3—N1—P1—Cl149.65 (10)
C2—C1—N1—P1−97.97 (14)C1—N1—P1—Cl1−137.45 (10)
  7 in total

1.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

2.  Cyclophosphamide structure. Molecular structure of 4-ketocyclophosphamide.

Authors:  N Camerman; A Camerman
Journal:  J Am Chem Soc       Date:  1973-07-25       Impact factor: 15.419

3.  Synthesis and antineoplastic activity of a novel series of phosphoramide mustard analogues of pyrimidine deoxyribonucleosides.

Authors:  T S Lin; P H Fischer; W H Prusoff
Journal:  J Med Chem       Date:  1980-11       Impact factor: 7.446

4.  6-Bromo-2-(4-nitro-phen-oxy)-3-(1-phenyl-ethyl)-3,4-dihydro-1,3,2-benzoxaza-phosphinine 2-oxide.

Authors:  V H H Surendra Babu; M Krishnaiah; K Srinivasulu; C Naga Raju; B Sreedhar
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-10-10

5.  Synthesis and antitumor properties of activated cyclophosphamide analogues.

Authors:  R F Borch; G W Canute
Journal:  J Med Chem       Date:  1991-10       Impact factor: 7.446

6.  Activated cyclophosphamide anticancer drugs: molecular structures of cis- and trans-4-hydroperoxyisophosphamides.

Authors:  A Camerman; H W Smith; N Camerman
Journal:  J Med Chem       Date:  1983-05       Impact factor: 7.446

7.  Synthesis and antitumor activity of cyclophosphamide analogues. 3. Preparation, molecular structure determination and anticancer screening of racemic cis- and trans-4-phenylcyclophosphamide.

Authors:  V L Boyd; G Zon; V L Himes; J K Stalick; A D Mighell; H V Secor
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.